What is the recommended treatment for a urinary tract infection caused by Acinetobacter baumannii, coagulase‑negative Staphylococcus, and Enterobacter cloacae?

Treatment of Polymicrobial UTI with Acinetobacter baumannii, Coagulase-Negative Staphylococcus, and Enterobacter cloacae

For this polymicrobial UTI, treat based on susceptibility testing with targeted therapy for each organism, prioritizing coverage of the most resistant pathogen (likely A. baumannii) while ensuring adequate coverage of all three organisms. 1

Initial Approach: Obtain Susceptibility Testing

• Antimicrobial susceptibility testing is essential before selecting definitive therapy, as resistance patterns vary significantly for all three organisms 1
• Differentiate between colonization and true infection, particularly for coagulase-negative Staphylococcus which may represent contamination 1
• Assess whether this is uncomplicated cystitis versus complicated UTI (cUTI), as treatment duration and intensity differ 1

Treatment Strategy Based on Resistance Patterns

For Carbapenem-Susceptible Organisms

If susceptibility testing shows all organisms are susceptible to standard agents:

• Carbapenems remain preferred for A. baumannii in areas with low carbapenem resistance (imipenem 0.5-1 g IV q6h or meropenem 2 g IV q8h) 2
• These agents also provide coverage for Enterobacter cloacae 3
• Add coverage for coagulase-negative Staphylococcus if clinically significant (linezolid 600 mg IV q12h or vancomycin) 1
• Treatment duration: 5-7 days for cUTI 1

For Carbapenem-Resistant A. baumannii (CRAB)

If A. baumannii is carbapenem-resistant, sulbactam-based therapy is preferred over polymyxins:

• Ampicillin-sulbactam 9-12 g/day in 3-4 divided doses (as 4-hour infusions) for isolates with sulbactam MIC ≤4 mg/L 2
• Sulbactam demonstrates better safety profile than colistin with comparable efficacy, including lower nephrotoxicity and mortality 2, 4
• Alternative: Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h if sulbactam unavailable or resistant 1, 2
• Polymyxin B 2-2.5 mg/kg loading dose, then 1.5-3 mg/kg/day in 2 doses is an alternative to colistin 2

For Enterobacter cloacae

Enterobacter cloacae treatment depends on ESBL production:

• If non-ESBL producing and susceptible: Cephalosporins, fluoroquinolones, or carbapenems based on susceptibility 3
• If ESBL-producing: Carbapenems (meropenem, imipenem, ertapenem) remain most reliable 3
• Alternative for cUTI due to carbapenem-resistant Enterobacterales (CRE):
  • Ceftazidime-avibactam 2.5 g IV q8h 1
  • Meropenem-vaborbactam 4 g IV q8h 1
  • Imipenem-cilastatin-relebactam 1.25 g IV q6h 1
  • Aminoglycosides: Amikacin 15 mg/kg/day IV once daily or gentamicin 5-7 mg/kg/day IV once daily 1

For Coagulase-Negative Staphylococcus

Treatment only if clinically significant (not contamination):

• Linezolid 600 mg IV or PO q12h for uncomplicated UTI 1
• Alternative options:
  • Fosfomycin 3 g PO single dose 1
  • Nitrofurantoin 100 mg PO q6h for 3-7 days 1
  • High-dose ampicillin 18-30 g IV daily in divided doses if susceptible 1

Specific Regimen Recommendations

For Uncomplicated Cystitis (Lower UTI)

Single-dose aminoglycoside therapy is appropriate if organisms are susceptible:

• Amikacin 15 mg/kg IV single dose 1
• Gentamicin 5-7 mg/kg IV single dose 1
• Plus fosfomycin 3 g PO single dose for Staphylococcus coverage 1

For Complicated UTI (cUTI)

Combination therapy targeting all three organisms:

1. If CRAB present: Ampicillin-sulbactam 9-12 g/day (provides A. baumannii and some Enterobacter coverage) 2, 5, 6
2. Plus targeted agent for Enterobacter based on susceptibility (carbapenem or newer beta-lactam/beta-lactamase inhibitor if resistant) 1
3. Plus linezolid 600 mg IV q12h if coagulase-negative Staphylococcus is clinically significant 1
4. Duration: 5-7 days 1

Critical Pitfalls to Avoid

• Do not use tigecycline monotherapy for A. baumannii UTI; it achieves suboptimal urinary concentrations despite in vitro activity 2
• Avoid fluoroquinolones for empiric therapy given high resistance rates in Asia-Pacific region (>50% for E. coli and similar patterns for other organisms) 7
• Do not use cefiderocol for pulmonary A. baumannii infections due to increased mortality, though UTI data are limited 8, 9
• Monitor renal function closely with polymyxin or aminoglycoside therapy; nephrotoxicity rates are 15-50% with colistin 2
• Coagulase-negative Staphylococcus may represent contamination rather than true infection; clinical correlation is essential 1

Monitoring and Source Control

• Obtain repeat urine culture 48-72 hours after treatment initiation to document microbiological response 1
• Remove or replace urinary catheters if present 1
• Assess for urinary tract obstruction or abscess requiring drainage 1
• Consider infectious diseases consultation for multidrug-resistant organisms 10